Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.

ABSTRACT:

Background

Identification of clinically relevant oncogenic drivers in advanced cancer is critical in selecting appropriate targeted therapy. Using next-generation sequencing (NGS)-based clinical cancer gene assay, we performed comprehensive genomic profiling (CGP) of advanced cases of lung adenocarcinoma.

Methods

Formalin-fixed paraffin-embedded tumors from 51 lung adenocarcinoma patients whose tumors previously tested negative for EGFR/KRAS/ALK by conventional methods were collected, and CGP was performed via hybridization capture of 4,557 exons from 287 cancer-related genes and 47 introns from 19 genes frequently rearranged in cancer.

Results

Genomic profiles of all 51 cases were obtained, with a median coverage of 564x and a total of 190 individual genomic alterati

SUBMITTER: Lim SM 

PROVIDER: S-EPMC5029692 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature